Arvinas (NASDAQ:ARVN) Shares Up 9.9% – What’s Next?

Arvinas, Inc. (NASDAQ:ARVN)’s stock price shot up 9.9% on Friday . The stock traded as high as $10.33 and last traded at $10.8810. 222,458 shares were traded during trading, a decline of 73% from the average session volume of 810,316 shares. The stock had previously closed at $9.90.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ARVN. BTIG Research boosted their price objective on Arvinas from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a report on Friday, April 10th. Wedbush boosted their price objective on Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Piper Sandler reissued an “overweight” rating and set a $20.00 price objective (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Finally, Zacks Research cut Arvinas from a “hold” rating to a “strong sell” rating in a report on Monday. Ten equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $13.88.

Arvinas Trading Up 6.2%

The company has a market capitalization of $672.22 million, a P/E ratio of -8.21 and a beta of 1.97. The business has a 50 day moving average price of $11.54 and a 200 day moving average price of $11.63.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). The company had revenue of $9.50 million during the quarter, compared to the consensus estimate of $37.26 million. Arvinas had a negative net margin of 30.77% and a negative return on equity of 14.25%. The business’s revenue was down 84.0% compared to the same quarter last year. During the same period last year, the company earned ($0.63) earnings per share. On average, analysts forecast that Arvinas, Inc. will post -3.26 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Briggs Morrison purchased 20,000 shares of the stock in a transaction dated Friday, March 6th. The stock was bought at an average cost of $13.40 per share, with a total value of $268,000.00. Following the purchase, the director directly owned 96,021 shares in the company, valued at $1,286,681.40. The trade was a 26.31% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Andrew Saik sold 5,134 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $11.89, for a total value of $61,043.26. Following the completion of the sale, the chief financial officer directly owned 159,267 shares of the company’s stock, valued at approximately $1,893,684.63. This trade represents a 3.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 63,864 shares of company stock worth $802,443 over the last quarter. Insiders own 4.73% of the company’s stock.

Institutional Trading of Arvinas

A number of large investors have recently bought and sold shares of ARVN. ProShare Advisors LLC grew its position in Arvinas by 7.2% in the fourth quarter. ProShare Advisors LLC now owns 14,827 shares of the company’s stock valued at $176,000 after acquiring an additional 993 shares during the last quarter. Intech Investment Management LLC grew its position in Arvinas by 3.6% in the third quarter. Intech Investment Management LLC now owns 32,653 shares of the company’s stock valued at $278,000 after acquiring an additional 1,125 shares during the last quarter. MetLife Investment Management LLC grew its position in Arvinas by 4.3% in the fourth quarter. MetLife Investment Management LLC now owns 33,810 shares of the company’s stock valued at $401,000 after acquiring an additional 1,381 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Arvinas by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after acquiring an additional 2,122 shares during the last quarter. Finally, Oxford Asset Management LLP grew its position in Arvinas by 15.5% in the second quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock valued at $123,000 after acquiring an additional 2,242 shares during the last quarter. 95.19% of the stock is owned by institutional investors.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.